Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLXNASDAQ:CCCCNASDAQ:CMPSNASDAQ:OPTN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$5.32+3.5%$3.88$1.58▼$7.27$473.93M-0.531.23 million shs759,329 shsCCCCC4 Therapeutics$1.74+6.7%$1.78$1.09▼$7.66$123.55M3.111.41 million shs1.14 million shsCMPSCOMPASS Pathways$4.19+2.2%$3.34$2.49▼$9.63$388.30M2.34797,755 shs630,372 shsOPTNOptiNose$9.40+0.1%$8.01$4.82▼$20.03$95.19M-0.8861,009 shs21,187 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals+3.50%-0.75%+40.74%+45.75%+175.65%CCCCC4 Therapeutics+6.75%+12.99%+14.47%-49.86%-73.39%CMPSCOMPASS Pathways+2.20%+9.69%+35.60%-2.78%-50.59%OPTNOptiNose+0.11%+1.29%+2.62%+58.78%-31.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMLXAmylyx Pharmaceuticals3.0728 of 5 stars3.41.00.00.02.84.21.3CCCCC4 Therapeutics2.4421 of 5 stars3.32.00.00.02.72.50.6CMPSCOMPASS Pathways2.4615 of 5 stars3.53.00.00.02.90.80.6OPTNOptiNose3.3079 of 5 stars1.05.00.04.22.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 2.86Moderate Buy$8.0050.38% UpsideCCCCC4 Therapeutics 2.60Moderate Buy$12.50618.39% UpsideCMPSCOMPASS Pathways 3.00Buy$20.20382.10% UpsideOPTNOptiNose 2.00Hold$9.00-4.26% DownsideCurrent Analyst Ratings BreakdownLatest OPTN, CCCC, AMLX, and CMPS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/7/2025AMLXAmylyx PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Outperform$3.00 ➝ $7.003/28/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/21/2025OPTNOptiNosePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$15.00 ➝ $9.003/21/2025OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$18.00 ➝ $9.003/20/2025OPTNOptiNosePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/20/2025OPTNOptiNoseLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$17.00 ➝ $9.003/5/2025AMLXAmylyx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/4/2025CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.00 ➝ $45.002/28/2025CMPSCOMPASS PathwaysCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $15.002/27/2025CMPSCOMPASS PathwaysStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$11.002/14/2025CCCCC4 TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals$87.37M5.42$0.97 per share5.51$6.42 per share0.83CCCCC4 Therapeutics$35.58M3.47N/AN/A$4.07 per share0.43CMPSCOMPASS PathwaysN/AN/AN/AN/A$3.65 per shareN/AOPTNOptiNose$78.23M1.22N/AN/A($11.56) per share-0.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals$49.27M-$4.44N/AN/AN/AN/A-36.97%-29.61%5/8/2025 (Estimated)CCCCC4 Therapeutics-$132.49M-$1.51N/AN/AN/A-313.35%-42.45%-27.55%5/6/2025 (Estimated)CMPSCOMPASS Pathways-$118.46M-$2.30N/AN/AN/AN/A-63.85%-51.97%5/8/2025 (Estimated)OPTNOptiNose-$35.48M-$2.88N/AN/AN/A-41.16%N/A-27.42%5/13/2025 (Estimated)Latest OPTN, CCCC, AMLX, and CMPS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CCCCC4 Therapeutics-$0.48N/AN/AN/A$3.54 millionN/A5/13/2025Q1 2025OPTNOptiNose-$0.74N/AN/AN/A$17.70 millionN/A5/8/2025Q1 2025AMLXAmylyx Pharmaceuticals-$0.43N/AN/AN/AN/AN/A5/8/2025Q1 2025CMPSCOMPASS Pathways-$0.47N/AN/AN/AN/AN/A3/26/2025Q4 2024OPTNOptiNose-$0.70-$0.03+$0.67-$0.03$21.02 million$21.47 million3/4/2025Q4 2024AMLXAmylyx Pharmaceuticals-$0.49-$0.55-$0.06-$0.55N/A($0.67) million2/27/2025Q4 2024CCCCC4 Therapeutics-$0.44-$0.49-$0.05-$0.49$4.43 million$5.18 million2/27/2025Q4 2024CMPSCOMPASS Pathways-$0.62-$0.63-$0.01-$0.63N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx Pharmaceuticals$1.0219.10%N/AN/A N/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/ACMPSCOMPASS PathwaysN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A4.554.55CCCCC4 TherapeuticsN/A6.316.31CMPSCOMPASS Pathways0.158.918.91OPTNOptiNoseN/A0.790.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%CCCCC4 Therapeutics78.81%CMPSCOMPASS Pathways46.19%OPTNOptiNose85.60%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals11.70%CCCCC4 Therapeutics8.55%CMPSCOMPASS Pathways4.25%OPTNOptiNose2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals20089.08 million60.53 millionOptionableCCCCC4 Therapeutics15071.01 million64.55 millionOptionableCMPSCOMPASS Pathways12092.67 million65.51 millionOptionableOPTNOptiNose19010.13 million9.83 millionNot OptionableOPTN, CCCC, AMLX, and CMPS HeadlinesRecent News About These CompaniesOptiNose, Inc. (NASDAQ:OPTN) Shares Sold by MVM Partners LLCMay 3 at 8:10 AM | marketbeat.comOptiNose, Inc. (NASDAQ:OPTN) Shares Sold by Nantahala Capital Management LLCApril 30 at 8:15 AM | marketbeat.comOPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTNApril 29, 2025 | businesswire.comGMT Capital Corp Decreases Stock Position in OptiNose, Inc. (NASDAQ:OPTN)April 25, 2025 | marketbeat.comOptiNose, Inc. (NASDAQ:OPTN) Short Interest UpdateApril 20, 2025 | marketbeat.comAster Capital Management DIFC Ltd Reduces Holdings in OptiNose, Inc. (NASDAQ:OPTN)April 13, 2025 | marketbeat.comOptinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational IncomeMarch 28, 2025 | msn.comOptinose reports Q4 EPS (3c) vs ($1.33) last yearMarch 27, 2025 | markets.businessinsider.comOptinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational HighlightsMarch 26, 2025 | markets.businessinsider.comOptiNose (OPTN) Reports Q4 Loss, Tops Revenue EstimatesMarch 26, 2025 | zacks.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of ShareholdersMarch 25, 2025 | morningstar.comWall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to TradeMarch 24, 2025 | zacks.comOptinose downgraded to Neutral from Buy at H.C. WainwrightMarch 22, 2025 | markets.businessinsider.comOPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTNMarch 21, 2025 | businesswire.comOPTN Stock Soars 53% on Inking $330M Deal to be Acquired by ParatekMarch 21, 2025 | zacks.comOptinose downgraded to Neutral from Overweight at Piper SandlerMarch 21, 2025 | markets.businessinsider.comOptinose downgraded to Hold from Buy at Lake StreetMarch 21, 2025 | markets.businessinsider.comWhy OptiNose Inc. (OPTN) Surged On Thursday?March 21, 2025 | msn.comLake Street Downgrades OptiNose (OPTN)March 21, 2025 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of ShareholdersMarch 21, 2025 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTNMarch 20, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOPTN, CCCC, AMLX, and CMPS Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$5.32 +0.18 (+3.50%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$5.34 +0.01 (+0.28%) As of 05/2/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.C4 Therapeutics NASDAQ:CCCC$1.74 +0.11 (+6.75%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.75 +0.01 (+0.57%) As of 05/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.COMPASS Pathways NASDAQ:CMPS$4.19 +0.09 (+2.20%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$4.14 -0.06 (-1.31%) As of 05/2/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.OptiNose NASDAQ:OPTN$9.40 +0.01 (+0.11%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$9.40 0.00 (0.00%) As of 05/2/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Microsoft Crushes Earnings, What’s Next for MSFT Stock? 3 Biotech Giants Gaining From U.S. Sales and Policy Shifts Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
